Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,600.00GBp
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
4,600.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,045,475
52-wk High
4,780.00
52-wk Low
2,940.50

Latest Key Developments (Source: Significant Developments)

Takeda Reaffirms Strategic & Financial Rationale For Shire Acquisition
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::ANNOUNCES PUBLICATION OF CIRCULAR AND NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS IN RELATION TO PROPOSED ACQUISITION OF SHIRE.REAFFIRMS STRATEGIC AND FINANCIAL RATIONALE FOR SHIRE ACQUISITION.  Full Article

Takeda Says To Hold Extraordinary Shareholders Meeting Dec 5 To Vote On Matters Related To Shire Acquisition
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SAYS TO HOLD EXTRAORDINARY SHAREHOLDERS MEETING DEC 5 TO VOTE ON MATTERS RELATED TO SHIRE ACQUISITION.  Full Article

Takeda Announces Issuance Of Unsecured Euro Denominated Senior Notes
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ANNOUNCES ISSUANCE OF UNSECURED EURO DENOMINATED SENIOR NOTES.  Full Article

Shire Q3 Revenue Rises 5 Pct To $3.87 Bln, Takeda Deal On Track To Close In H1 2019
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Shire PLC ::SHIRE PLC - PRODUCT SALES GROWTH OF 6% AND CONTINUES TO EXECUTE AGAINST KEY PRIORITIES IN Q3 2018.SHIRE PLC - TAKEDA'S PROPOSED ACQUISITION OF SHIRE REMAINS ON TRACK TO CLOSE IN H1 2019.SHIRE PLC - Q3 TOTAL REVENUES OF $3,872 MILLION REPRESENTING GROWTH OF 5%.SHIRE PLC - Q3 OPERATING INCOME INCREASED 35% TO $956 MILLION.SHIRE PLC - QTRLY DILUTED EARNINGS PER ADS $1.75.SHIRE PLC - QTRLY NON GAAP DILUTED EARNINGS PER ADS $3.64.SHIRE PLC - Q3 NON GAAP EBITDA MARGIN WAS SLIGHTLY DOWN TO 42% (Q3 2017: 44%).SHIRE PLC - CONTINUE TO EXPECT TO ACHIEVE MID-FORTIES NON GAAP EBITDA MARGIN BY 2020.SHIRE PLC - PROJECTED 2020 REVENUE TARGET UPDATED TO $16.5 - $17.5 BILLION, REFLECTING REMOVAL OF $0.5 BILLION OF ONCOLOGY SALES IN ORIGINAL PROJECTION.SHIRE PLC - SEES FY TOTAL REVENUE $15.3 - $15.8 BILLION.SHIRE PLC - SEES FY DILUTED EARNINGS PER ADS $7.17 - $7.77.SHIRE PLC - SEES FY NON GAAP DILUTED EARNINGS PER ADS $14.77 - $15.37.  Full Article

Takeda CEO Says R&D Budget Will Be More Than 400 Bln Yen After Shire Acquisition, Making Takeda More Competitive Globally
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>: :TAKEDA CEO SAYS RESEARCH AND DEVELOPMENT BUDGET WILL BE MORE THAN 400 BILLION YEN ($3.5 BILLION) AFTER SHIRE ACQUISITION, MAKING TAKEDA MORE COMPETITIVE GLOBALLY .  Full Article

Takeda Announces New Financing Agreements Related To Shire Deal
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::ANNOUNCES EXECUTION OF SENIOR SHORT TERM LOAN FACILITY AGREEMENT AND SUBORDINATED SYNDICATED LOAN AGREEMENT.ALSO ANNOUNCES EXECUTION OF SECOND AMENDMENT TO BRIDGE CREDIT AGREEMENT IN CONNECTION WITH PROPOSED ACQUISITION OF SHIRE.ENTERED INTO A SENIOR SHORT TERM LOAN FACILITY AGREEMENT FOR UP TO 500 BILLION JAPANESE YEN.SENIOR SHORT TERM LOAN FACILITY WILL FINANCE A PORTION OF FUNDS NECESSARY FOR ACQUISITION OF SHIRE.ALSO ENTERED INTO A SUBORDINATED SYNDICATED LOAN AGREEMENT FOR UP TO 500 BILLION JAPANESE YEN.AGREEMENTS SUPPORT INTENTION TO MAINTAIN DIVIDEND POLICY & INVESTMENT GRADE CREDIT RATING FOLLOWING SHIRE DEAL CLOSE.  Full Article

Shire Files Submission For U.S. FDA Approval To Manufacture Flexbumin
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Shire PLC ::SHIRE FILES SUBMISSION FOR U.S. FDA APPROVAL TO MANUFACTURE FLEXBUMIN® AT NEW PLASMA MANUFACTURING FACILITY NEAR COVINGTON, GEORGIA.  Full Article

EU Medicines Agency Recommends Approval Of Shire's Takhzyro
Friday, 19 Oct 2018 

Oct 19 (Reuters) - EU Medicines Agency::TAKHZYRO, DRUG FOR RARE SWELLING DISORDER.EU MEDICINES AGENCY - RECOMMENDS APPROVAL OF ASTRAZENECA'S BEVESPI AEROSPHERE FOR TREATMENT OF COPD.EU MEDICINES AGENCY - MYLAN'S OGIVRI (TRASTUZUMAB) RECEIVED POSITIVE OPINION TO TREAT BREAST AND GASTRIC CANCER.  Full Article

Shire Says Receives Approval Of Firazyr In Japan
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Shire PLC ::SHIRE RECEIVES APPROVAL OF FIRAZYR® (ICATIBANT INJECTION) FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA (HAE) ATTACKS IN JAPAN.SHIRE PLC - STUDY SHOWED THAT FIRAZYR WAS WELL TOLERATED AND DEMONSTRATED SYMPTOM RELIEF DURING AN ACUTE HAE ATTACK THROUGH A SINGLE INJECTION.  Full Article

Takeda Is Said To Weigh Sale Of Shire Eye Care Drug To Cut Debt - Bloomberg
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - :TAKEDA IS SAID TO WEIGH SALE OF SHIRE EYE CARE DRUG TO CUT DEBT - BLOOMBERG, CITING SOURCES.  Full Article

EU mergers and takeovers (Nov 19)

BRUSSELS, Nov 19 The following are mergers under review by the European Commission and a brief guide to the EU merger process: